A big bet on particularly precise precision medicine
The field of targeted cancer therapy has been homing in on ever-rarer genetic mutations, hoping to find highly effective drugs for tiny patient populations. Elevate Oncology, an emerging startup, aims to be especially precise, targeting a defect present on just 0.2% of tumors.
As STAT’s Elizabeth Cooney reports, Elevate raised $32.5 million to develop a drug against NRG1, a genomic fusion found in about 3,000 to 5,000 solid tumors in the U.S. each year. Elevate licensed its drug, an antibody, from Merrimack Pharmaceuticals last year.
The plan is to move straight into Phase 2, recruiting patients with a variety of solid tumors to test whether the drug can make a difference. If everything goes according to plan, Elevate could seek a tumor-agnostic approval.
Read more.
As STAT’s Elizabeth Cooney reports, Elevate raised $32.5 million to develop a drug against NRG1, a genomic fusion found in about 3,000 to 5,000 solid tumors in the U.S. each year. Elevate licensed its drug, an antibody, from Merrimack Pharmaceuticals last year.
The plan is to move straight into Phase 2, recruiting patients with a variety of solid tumors to test whether the drug can make a difference. If everything goes according to plan, Elevate could seek a tumor-agnostic approval.
Read more.
No hay comentarios:
Publicar un comentario